Chemotherapy for advanced hormone refractory prostate cancer (Q33800983)

29 July 2017

1 reference

title

Chemotherapy for advanced hormone refractory prostate cancer (English)

1 reference

29 July 2017

1 reference

1 reference

Petrylak DP

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 December 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

54

1 reference

29 July 2017

issue

6A Suppl

1 reference

29 July 2017

page(s)

30-35

1 reference

29 July 2017

cites work

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5

7 January 2021

10.1016/S0090-4295(99)00452-5

Identifiers

DOI

1 reference

29 July 2017

1 reference